about
The Danish National Chronic Lymphocytic Leukemia Registry[Multi-facetted clinical presentation of thrombotic thrombocytopenic purpura].Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.B-cell receptor signaling as a driver of lymphoma development and evolution.Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyDifferent spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.Expression analyses of human cleft palate tissue suggest a role for osteopontin and immune related factors in palatal developmentImproved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patientsTowards targeted therapy of chronic lymphocytic leukemia.Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.[Washington DC vs. Copenhagen].Highly glycosylated alpha1-acid glycoprotein is synthesized in myelocytes, stored in secondary granules, and released by activated neutrophils.Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death.Serglycin proteoglycan is not implicated in localizing exocrine pancreas enzymes to zymogen granules.Quality of life and symptoms in patients with malignant diseases admitted to a comprehensive cancer centre.Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.[Positive results with haematology webcasting for junior doctors].[Targeted treatment of chronic lymphocytic leukaemia].Cocreated Smartphone App to Improve the Quality of Life of Adolescents and Young Adults with Cancer (Kræftværket): Protocol for a Quantitative and Qualitative Evaluation.Targeting Bruton's Tyrosine Kinase Across B-Cell MalignanciesPain characteristics and management of inpatients admitted to a comprehensive cancer centre: a cross-sectional studyNeutrophil elastase depends on serglycin proteoglycan for localization in granulesSerglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemiaThe CLL-IPI applied in a population-based cohortUsing Cocreation in the Process of Designing a Smartphone App for Adolescents and Young Adults With Cancer: Prototype Development StudyMachine learning can identify newly diagnosed patients with CLL at high risk of infection[In Process Citation]
P50
Q28078144-72AF142A-26B5-4FE5-B0CB-8CA532B2AD0CQ33382982-476B1404-819D-476C-A2D4-77956848DFEBQ33419580-E9E2E169-95BE-4886-B381-C96AF48F9E00Q33774491-D3B5C7EF-FAC9-4BAE-AC76-1BA5CDFCE9ACQ34289493-C491260D-FEDD-43D2-9690-75D643C1F480Q34398579-70EA212C-895F-4EC7-A939-C4EA043E1929Q36337598-D1DB5100-08A7-42CD-928E-BF68A1153ECFQ36437030-FEC150D0-1C36-4801-9794-4C1ACD6A08D4Q36759124-EF139E24-0D21-42C8-BF01-1D82B060482FQ37140491-F7CED349-B2D8-4D32-8C87-75F46861D4F7Q37184993-9B75F1E5-321D-41B2-B307-17F0098D4143Q37489992-EA1F1E2C-B292-430D-A046-7D0D7102B104Q38135350-ECC3A3EF-5954-4A76-B335-872B7A2C7729Q38917132-ED036444-1BB2-4B6C-B2AF-7574DF6E7A32Q40188830-A6A3B573-96CE-465E-8385-E95E07A07683Q40389000-21DB59D2-1154-4E08-8662-E8A5A283933FQ40412679-7DC76106-110B-42FA-ABAE-B53507E33C3EQ40802888-079D5E7C-D8B6-46E9-A868-6B20A44A7A62Q45327535-903C74D7-8989-46AF-9C7A-5B47CF0F6F73Q45514142-15888DEB-FB39-4CDE-948C-28CD1BF55D2CQ46074725-DDE6A602-170C-44E8-BC32-B5901453B980Q46566477-8E31D014-6E34-4ABE-B8B2-55149665F1D3Q47938242-8BCF22E2-17D8-4056-B5F8-1E784D0036BFQ48198290-1951289B-A61F-4B64-946C-D402392E8AB1Q48716913-A832E176-4EDF-4783-974C-FA3ECCC3F097Q50134687-780D78F7-7ABD-4B58-B784-DDEF6301267FQ50541044-464DAEEE-EA18-42B0-9ECC-7FC6F89C6177Q54312920-01A8BB47-3569-4A3B-B158-48DCB3543CA9Q55255223-B0113B55-CBBE-4AD2-9B84-593BE16C6748Q58613953-673750C1-E2B2-4666-AC28-1AB474489DFDQ60679749-47B5C26A-BD08-49E0-AA3C-747C03263A73Q79710976-9CBC7896-585F-4C57-A02E-E04A09F30336Q81422106-92CFDC24-7466-475F-B7AA-A7B29BDCD3DAQ88291952-27564C6D-F18F-41CA-A2B2-20276C795859Q91232699-1E04098E-9919-45B9-B7AC-934CC2D6F727Q92740078-0565BD6E-D991-47C9-98AC-6DFB61B0EDCBQ95511609-7C0FD2C5-39C7-40DD-A33D-3D92AC655255
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carsten Niemann
@ast
Carsten Niemann
@en
Carsten Niemann
@es
Carsten Niemann
@nl
Carsten Niemann
@sl
type
label
Carsten Niemann
@ast
Carsten Niemann
@en
Carsten Niemann
@es
Carsten Niemann
@nl
Carsten Niemann
@sl
prefLabel
Carsten Niemann
@ast
Carsten Niemann
@en
Carsten Niemann
@es
Carsten Niemann
@nl
Carsten Niemann
@sl
P106
P31
P496
0000-0001-9880-5242